72 pages matching percent in this book
Results 1-3 of 72
What people are saying - Write a review
We haven't found any reviews in the usual places.
active Amgen analysis approval phase Approval Time months approved drug AstraZeneca biopharmaceuticals biotech biotechnology cancer Cardiovascular CBER CDER clinical development clinical phase clinical research clinical trials cohort compounds cost per approved CRO usage database Dermatology DiMasi disease Disorders Division Drug Development drugs approved estimates fast track FDA First Action FDA Second Action firms Genentech GlaxoSmithKline global Goldman Sachs growth increase IND filing innovation late-stage launch Lehman Brothers Lilly mean clinical Median medicines Merck million NCEs NDA approval NME approvals NMEs Novartis oncology orphan drug penod percent period Pfizer pharma companies pharmaceutical companies Pharmaceutical R&D Pharmaprojects Phase Phase PhRMA preclinical priority projects R&D Pipeline R&D spending regulatory Roche Sanofi-Aventis Source Sponsor Response Statistics Study of Drug Success Rates Costs/Complexity survey targets therapeutic areas Therapeutic Category Thomson CenterWatch tnals Tufts Center Tufts CSDD vaccines Wyeth